TCGA-OR-A5L5-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.458
- INTERFERON_ALPHA_RESPONSE+0.453
- INTERFERON_GAMMA_RESPONSE+0.405
- IL6_JAK_STAT3_SIGNALING+0.328
- OXIDATIVE_PHOSPHORYLATION+0.277
- BILE_ACID_METABOLISM+0.272
- INFLAMMATORY_RESPONSE+0.263
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.244
- KRAS_SIGNALING_UP+0.226
- APOPTOSIS+0.212
Top 10 suppressed
- E2F_TARGETS-0.601
- G2M_CHECKPOINT-0.585
- MITOTIC_SPINDLE-0.428
- MYC_TARGETS_V2-0.394
- WNT_BETA_CATENIN_SIGNALING-0.383
- CHOLESTEROL_HOMEOSTASIS-0.333
- UNFOLDED_PROTEIN_RESPONSE-0.301
- MYC_TARGETS_V1-0.297
- TGF_BETA_SIGNALING-0.279
- MTORC1_SIGNALING-0.203
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598283 | fetal | fetal | 0.897 |
| 2 | MDT-AP-2181 | Med | Medulloblastoma | 0.884 |
| 3 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.876 |
| 4 | SRR1430570 | GTEX | — | 0.869 |
| 5 | C3L-02560 | — | cohortA1 | 0.867 |
| 6 | 20030012.LumA | — | A | 0.860 |
| 7 | TCGA-34-5234-01A-01R-1635-07 | — | cohortSQ1 | 0.858 |
| 8 | SRR656167 | GTEX | — | 0.856 |
| 9 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.855 |
| 10 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.458 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.453 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.405 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.328 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.277 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.272 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.263 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.244 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.226 | Inavolisib | — uncovered |
| APOPTOSIS | 0.212 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.206 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.197 | Inavolisib | — uncovered |
| MYOGENESIS | 0.189 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.188 | Inavolisib | — uncovered |
| COMPLEMENT | 0.176 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.162 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.162 | Inavolisib | — uncovered |
| COAGULATION | 0.159 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.143 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.141 | Remibrutinib | — uncovered |